The algorithm sorts patients into groups, who need grading and don't need grading. The ophthalmologists in the team/system can then focus on diagnosing and treating patients who actually need their time. In this way, RetinaLyze® reduces up to 60% of the manual workload.
RetinaLyze® provides instant results on automated screenings for Diabetic Retinopathy, Age-related Macular Degeneration and Glaucoma. The built-in telemedicine platform also allows operators to communicate with remote graders to receive manual assessments.
Security is important to us. As standard, all communication is encrypted. A middle man won’t be able to view or edit images, results or the client information. RetinaLyze is CE-marked and uses the highest level of encryption available today.
RetinaLyze® is a simple system and has been developed with the aim of being easy to use and easy to learn for clinicians as well as non-clinicians. The system can be easily adapted to fit the needs for a single retail store or clinic, a large chain of optometrists or hospitals as well as a rural screening camp.
A paper has been accepted in the prestigious British Journal of Ophthalmology, demonstrating that Laguna ONhE/RetinaLyze Glaucoma has a diagnostic capability similar to a modern and expensive Angio-OCT.
The entire RetinaLyze team and their partners were close to our customers this year. At a total of six exhibition stands, visitors were able to learn more about eye screening using artificial intelligence.